Use and complications of high-dose disodium etidronate therapy in fibrodysplasia ossificans progressiva†
References (12)
Myositis ossificans progressiva
Am J Med
(1964)- et al.
Diphosphonates in the treatment of myositis ossificans
Lancet
(1969) - et al.
Treatment of myositis ossificans progressiva with diphosphonate
Lancet
(1972) Heritable disorders of connective tissue
- et al.
Experience with disodium etidronate in diseases of ectopic calcification
- et al.
Diphosphonate treatment in bone disease
N Engl J Med
(1973)
There are more references available in the full text version of this article.
Cited by (46)
Severe limitation in jaw movement in a patient with fibrodysplasia ossificans progressiva: a case report
2006, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and EndodontologyThe Spectrum of Pediatric Osteoporosis
2003, Pediatric Bone: Biology & DiseasesBiphosphonates in children: Present and future
2002, Archives de PediatrieExpanding role of bisphosphonate therapy in children
1999, Journal of PediatricsThe use of bisphosphonates in pediatrics
2014, Hormone Research in PaediatricsClinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice
2013, Journal of Bone and Mineral Metabolism
- †
Supported in part by National Institutes of Health grant GM795.
Copyright © 1977 Published by Mosby, Inc.